阿西米尼治疗复发或难治性费城染色体阳性急性淋巴细胞白血病。

IF 7.1 1区医学 Q1 HEMATOLOGY

Blood advances Pub Date : 2025-09-23 DOI:10.1182/bloodadvances.2025016665

Mathilde Chanut, Aurélie Cabannes-Hamy, Marie Balsat, Nassim Sahki, Emmanuel Raffoux, Yosr Hicheri, Bruno Lioure, Lucie Laemmel, Thibaut Leguay, Victoria Cacheux, Maria Pilar Gallego-Hernanz, Andrea Pieragostini, Gabrielle Roth-Guepin, Ludovic Gabellier, Nathalie Denizon, Lise Willems, Quentin Cabrera, Sylvain Chantepie, Valérie Coiteux, Claudie Capdupuy, Martin Carré, Antoine Machet, Juliette Lambert, Sandrine Roux, Franck-Emmanuel Nicolini, Nicolas Boissel, Emmanuelle Clappier, Rathana Kim, Philippe Rousselot

引用次数: 0

摘要

Asciminib （ASC）是一种BCR::ABL1的变张抑制剂，结合ABL1蛋白的肉豆肉酰化位点。我们报告了在法国回顾性收集的41例复发费城染色体阳性急性淋巴细胞白血病（Ph+ ALL）和慢性髓性白血病（LBC-CML）的淋巴细胞危象中使用ASC。中位年龄56岁（范围19-84岁）。大多数患者（78%）接受ASC作为三线或后期治疗，其中93%之前接受过ponatinib治疗。35例分析患者中有27例发生BCR::ABL1突变，包括T315I （n=18）或复合突变（n=8）。83%的患者服用200 mg BID的ASC，单独（n=20）或联合（n=21）。总体而言，36例可评估患者中有30例实现了复合完全缓解（CR/CRi），包括可测量的残留疾病阴性（由BCR::ABL1/ABL1定义）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Asciminib for relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Blood advances Medicine-Hematology

CiteScore

12.70

自引率

2.70%

发文量

840

期刊介绍： Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016. Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.